白三烯受体拮抗剂疗法
Leukotriene receptor antagonist therapy.
作者信息
Dempsey O J
机构信息
Asthma and Allergy Research Group, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK.
出版信息
Postgrad Med J. 2000 Dec;76(902):767-73. doi: 10.1136/pmj.76.902.767.
Abstract
Leukotriene receptor antagonists (LTRA) are a new class of drugs for asthma treatment, available in tablet form. Their unique mechanism of action results in a combination of both bronchodilator and anti-inflammatory effects. While their optimal place in asthma management is still under review, LTRA represent an important advance in asthma pharmacotherapy.
摘要
白三烯受体拮抗剂（LTRA）是一类用于治疗哮喘的新型药物，有片剂剂型。其独特的作用机制产生了支气管扩张和抗炎的双重效果。虽然它们在哮喘管理中的最佳地位仍在研究中，但白三烯受体拮抗剂是哮喘药物治疗的一项重要进展。
Zotero 插件